Table 3. Secondary Per-Protocol Results: Effect of Zinc vs Placebo on Markers of Mortality, HIV Progression, Cardiovascular Disease Risk and Inflammation.
| Marker | Zinc group (n = 64) | Placebo group (n = 63) | Adjusted mean difference (95% CI) | P value |
|---|---|---|---|---|
| Change from baseline to 18 mo | ||||
| Veterans Aging Cohort Study Index score | ||||
| Mean (SD) | 0.22 (15.2) | 7.72 (16.9) | −7.49 (−13.74 to −1.23) | .02 |
| Median (IQR) | 0 (−7.0 to 6.0) | 7.0 (−6.0 to 17.0) | ||
| CD4 cell count, cells/mm3 | ||||
| Mean (SD) | −129.5 (222.0) | −188.9 (225.0) | 47.4 (−32.9 to 127.8) | .25 |
| Median (IQR) | −90.4 (−242.3 to 12.3) | −146.2 (−295.4 to −51.0) | ||
| At 18 mo | ||||
| Reynolds Risk Scorea | ||||
| Mean (SD) | −0.21 (0.8) | −0.12 (0.8) | −0.083 (−0.282 to 0.116) | .41 |
| Median (IQR) | −0.25 (−0.70 to 0.30) | −0.11 (−0.62 to 0.54) | ||
| Interleukin-6, pg/mLa | ||||
| Mean (SD) | −0.02 (0.9) | 0.20 (0.8) | 0.012 (−0.25 to 0.28) | .93 |
| Median (IQR) | 0.06 (−0.83 to 0.57) | 0.20 (−0.43 to 0.72) | ||
| Dimerized plasmin fragment D, μg/mL fibrinogen equivalent unitsa | ||||
| Mean (SD) | −0.97 (1.0) | −0.71 (1.1) | −0.31 (−0.65 to 0.04) | .08 |
| Median (IQR) | −0.93 (−1.56 to −0.27) | −0.71 (−1.47 to 0.06) | ||
| Soluble CD14, mean (SD), ng/mL | 2092.08 (464.2) | 2149.46 (507.2) | −6.03 (−162.31 to 150.25) | .95 |
| Intestinal fatty acid binding protein, mean (SD), pg/mLa | 7.17 (0.4) | 7.03 (0.5) | 0.11 (−0.06 to 0.28) | .21 |
| Lipopolysaccharide binding protein, mean (SD), ng/mLa | 8.12 (0.5) | 8.21 (0.5) | −0.10 (−0.27 to 0.07) | .24 |
Abbreviation: IQR, interquartile range.
SI conversion factor: To convert dimerized plasmin fragment D to nmol/L, multiply by 5.476.
a
Natural log-transformation.